Oxycodone does not affect placental circulatory physiology during the early first stage of labor-A randomized trial.
circulation
exposure
fetus
labor
newborn
oxycodone
physiology
placenta
Journal
Acta obstetricia et gynecologica Scandinavica
ISSN: 1600-0412
Titre abrégé: Acta Obstet Gynecol Scand
Pays: United States
ID NLM: 0370343
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
revised:
23
04
2023
received:
23
12
2022
accepted:
15
05
2023
medline:
31
7
2023
pubmed:
22
6
2023
entrez:
22
6
2023
Statut:
ppublish
Résumé
Opioids are used for pain relief during the first stage of labor. Oxycodone can cause maternal hypotension that may modify utero- and fetoplacental circulatory physiology. We hypothesized that maternal intravenous (i.v.) oxycodone has no detrimental effect on utero- and fetoplacental hemodynamics during the early first stage of labor. Twenty-two parturients requiring pain relief during the first stage of labor were randomized in a double-blinded and placebo-controlled study. By Doppler ultrasonography, both uterine artery (Ut) and umbilical vein (UV) volume blood flows (Q), Ut pulsatility index (PI), and Ut vascular resistance (RUt) were calculated. Blood flow velocity waveforms were obtained between uterine contractions. After baseline measurements, women received oxycodone 0.05 mg/kg or a placebo intravenous. Doppler ultrasonography was repeated up to 120 min after the first drug administration. The second dose of oxycodone 0.05 mg/kg was allowed at 60 min to all parturients with contraction pain ≥5/10. Maternal plasma samples were collected at each study phase and after delivery with umbilical cord plasma samples, to measure oxycodone concentrations. gov identifier (NCT no. NCT02573831). At baseline, mean QUt and QUV did not differ significantly between the placebo-first (478 mL/min and 57 mL/min/kg) and the oxycodone-first (561 mL/min and 71 mL/min/kg) groups. In addition, RUt and Ut PI were comparable between the groups. Following oxycodone at 60 min, mean QUt and QUV (714 mL/min and 52 mL/min/kg) were similar to the placebo-first (520 mL/min and 55 mL/min/kg) group. Furthermore, all the measured parameters were comparable to the baseline values. At 60 min after the first study drug administration, all the parturients in the placebo-first group needed intravenous oxycodone 0.05 mg/kg. At 120 min, we found no statistically significant change in any of the measured parameters. No significant correlation was found between maternal oxycodone concentration and QUt or QUV. Furthermore, newborn oxycodone concentration did not correlate with QUV. Oxycodone did not have any detrimental effect on either utero- or fetoplacental circulatory physiology during the early first stage of labor. Maternal plasma oxycodone did not correlate with utero- and fetoplacental hemodynamics. No correlation was found between newborn oxycodone concentration and fetoplacental hemodynamics.
Identifiants
pubmed: 37344997
doi: 10.1111/aogs.14603
pmc: PMC10378015
doi:
Substances chimiques
Oxycodone
CD35PMG570
Banques de données
ClinicalTrials.gov
['NCT02573831']
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1063-1072Subventions
Organisme : The governmental VTR fund, Hospital District of Northern Savo
Organisme : University of Eastern Finland
Informations de copyright
© 2023 The Authors. Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG).
Références
Circ Res. 1978 Apr;42(4):474-8
pubmed: 630663
Acta Obstet Gynecol Scand. 2023 Aug;102(8):1063-1072
pubmed: 37344997
Cochrane Database Syst Rev. 2018 Jun 05;6:CD007396
pubmed: 29870574
Ultrasound Med Biol. 1990;16(1):19-27
pubmed: 2181760
Ultrasound Obstet Gynecol. 2008 Sep;32(4):587-91
pubmed: 18618412
Eur J Obstet Gynecol Reprod Biol. 2013 Jun;168(2):161-6
pubmed: 23398725
Int J Gynaecol Obstet. 2015 Oct;131(1):13-24
pubmed: 26433401
Clin Pharmacokinet. 2019 Jun;58(6):705-725
pubmed: 30652261
Circ Res. 1976 Apr;38(4):262-6
pubmed: 1260968
N Engl J Med. 1969 Dec 18;281(25):1389-93
pubmed: 5355454
Basic Clin Pharmacol Toxicol. 2012 Sep;111(3):182-8
pubmed: 22448718
Ultrasound Obstet Gynecol. 2007 Apr;29(4):401-6
pubmed: 17390334
Placenta. 2020 Jan 15;90:103-108
pubmed: 32056540
Arch Toxicol. 2021 Aug;95(8):2627-2642
pubmed: 33974096
Br J Anaesth. 2004 Dec;93(6):825-32
pubmed: 15465843
Cochrane Database Syst Rev. 2018 May 21;5:CD000331
pubmed: 29781504
Prenat Diagn. 2005 Feb;25(2):99-111
pubmed: 15712315
Anesthesiology. 1993 Feb;78(2):231-6
pubmed: 8439016
BJOG. 2010 Jun;117(7):837-44
pubmed: 20353457
Br J Anaesth. 2012 Aug;109(2):144-54
pubmed: 22735301
Br J Clin Pharmacol. 2017 Apr;83(4):791-800
pubmed: 27780305
Ultrasound Obstet Gynecol. 2013 Feb;41(2):233-39
pubmed: 23371348
J Dev Physiol. 1989 Dec;12(6):305-22
pubmed: 2701106
Acta Anaesthesiol Scand. 2020 May;64(5):685-690
pubmed: 31950485
Br J Anaesth. 2006 Feb;96(2):231-7
pubmed: 16377647